PTO/SB/08a (07-09)

Approved for use through 07/31/2012, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to re on of information unless it contains a valid OMB control num Complete if Known Substitute for form 1449/PTO Application Number 10/517074 INFORMATION DISCLOSURE Filing Date June 06, 2003 First Named Inventor Hohneker, John Arthur et al. STATEMENT BY APPLICANT Art unit 1642 (Use as many sheets as necessary) Examiner Name Fetterolf, Brandon J of Attorney Docket Number PAT032515-US-PCT

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (Flores)	Publication Date MM-DD-YYYY	Name of Petentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Retevant Figures Appear
		US-			rigules Appear
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Cite	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Neme of Patentee or	Pages, Columns, Lines,	Г
Initiels*	NO.	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (Fknown)	MM-DD-11111	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	ľ
		JP 2002504540	02-12-2002	Sloan-Kettering Institute for Cancer research	Corres. to WO99/43653 enclosed	C
		WO 02/022577	03-21-2002	Novartis AG		[
			1			C

1	Examiner		Date			1
	Signature		Cons	idered		ı
	*EXAMINER: Ini	tial if reference considered, whether or not citation is in conformance with N	IPEP 609.	Draw a line	e through citation if not in conformance	_

"E-Anwirette: small a reverence considered, whether or not citation is in common with MPEP 909. If you at init through clistion if not in conformation and not considered, include copy of this form with the act communication to applicant." Applicant is unique citation selsgation number (optional). See Kind Codes of USFP Posteri Documents at <u>www.uspto.gov.or</u> MPEP 901.04. \*Enter Office that its year of the common to the selection of the Shardard \$3.3. \*Shardard \$3.3. \*Sharda

This collection of information is required by 97 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file and by the USPTO by process) an application. Confidentially is governed by 38 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including aghering, preparing, and submitting the completed application form to the USPTO. There will vary depending upon the individual case. An openments on the mount of three you require to complete in file man and/or suppositions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. 80x 1450, Alexandria, VA 2231-4450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandria, VA 2231-4450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (07-09)

PTC/SB/08b (07-09)
Approved for use through 07751/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Inder the Paperwork Re	duction Act of 19	95, no persons are required	to respond to a collection of information u	nless it contains a valid OMB control num		
Substitute for f	orm 1449/PTO			Complete if Known			
outourano ioi i			•	Application Number	10/517074		
INFORMATION DISCLOSURE				Filing Date	June 06, 2003		
				First Named Inventor	Hohneker, John Arthur et al.		
STATEMENT BY APPLICANT (Use as many sheets as necessary)				Art unit	1642		
	(occ ac many	onceto do neo	cooury)	Examiner Name	Fetterolf, Brandon J		
Sheet	2	of	2	Attorney Docket Number	PAT032515-US-PCT		

	_	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Yoshida, Minoru et al., "Histone deacetylase as a new target for cancer chemotherapy", cancer Chemotherapy Pharmacol, 2001, vol 48 (suppl. 1), pp S20-S26	
		Munster, PN et at, "The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells", Cancer Research, 2001 Dec 1; vol. 61; pp 8492-7.	_
			-
	-		
			<u></u>
		*	

Examiner	Date	-
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance

\*\*EAAMMEN: mital if referred considered, whether of no citation is in conformance with MPEP 509. Draw a line through citation of not in conformance and not considered. Include copy of this form with the next communication to application.

\*\*EAAMMEN and the conformation is required by 37 CFR 1.8. The information large and in obtain or retain a benefit by the policy which is to file (end by the USPT 0.0 process) an application. Confidentiality is operated by 38 CFR 1.8. The information large and the complete, including gathering, preparing, and submitting the completed application form to the USPT.O. Time will very depending upon the highly complete, including gathering, preparing, and submitting the completed application form to the USPT.O. Time will very depending upon the highly case. Any comments on the amount of time your required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Platent and Trademark Office, P.O. Box 1469, Alexandris, VA.22313-1460. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patients, P.O. Box 1469, Alexandris, VA.22313-1450.